The Colorado board’s choice of drugs to review elucidates one of the thorniest questions it must wrangle with: Would lowering the price tag for rare-disease medications lead manufacturers to pull out of the state or limit their availability?
A Colorado board has named five drugs it will review for affordability and potential cost caps. But patients with cystic fibrosis worry they will lose a life-changing therapy.